Abstract
BackgroundIn preclinical studies, müllerian inhibiting substance (MIS) has a protective affect against breast cancer. Our objective was to determine whether serum MIS concentrations were associated with cancerous or precancerous lesions. Blood from 30 premenopausal women was collected and serum extracted prior to their undergoing breast biopsy to assess a suspicious lesion found on imaging or physical examination. Based on biopsy results, the serum specimens were grouped as cancer (invasive or ductal carcinoma in situ), precancer (atypical hyperplasia or lobular carcinoma in situ), or benign.FindingsSerum from women with cancer and precancer (p = .0009) had lower MIS levels than serum from women with benign disease.ConclusionOur findings provide preliminary evidence for MIS being associated with current breast cancer risk, which should be validated in a larger population.
Highlights
Müllerian inhibiting substance (MIS), known as anti-müllerian hormone, is produced by the granulosa cells of growing ovarian follicles
Our findings provide preliminary evidence for müllerian inhibiting substance (MIS) being associated with current breast cancer risk, which should be validated in a larger population
Thirty blood samples were prospectively collected in serum separator tubes from premenopausal women 38-50 years of age scheduled to undergo diagnostic breast biopsy to determine the benign or malignant nature of a suspicious breast lesion identified on imaging or physical examination
Summary
Müllerian inhibiting substance (MIS), known as anti-müllerian hormone, is produced by the granulosa cells of growing ovarian follicles. MIS levels have recently been linked to breast cancer risk [2]. MIS inhibits the growth of cultured breast cancer cells through G1 arrest and the induction of apoptosis [5,6]. An eight-fold increase in the ratio of apoptotic cells in murine mammary tissue was observed after MIS injection [6]. Based on these observations, our hypothesis was that MIS would decrease breast cancer risk in premenopausal women, and that MIS serum levels would be different in. Müllerian inhibiting substance (MIS) has a protective affect against breast cancer. Our objective was to determine whether serum MIS concentrations were associated with cancerous or precancerous lesions. The serum specimens were grouped as cancer (invasive or ductal carcinoma in situ), precancer (atypical hyperplasia or lobular carcinoma in situ), or benign
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
